market

Genfit stock rallies 20% after hours on data for liver disease drug


Anatomy of human body with liver. 3d illustration

Mohammed Haneefa Nizamudeen

Shares of Genfit (NASDAQ:GNFT) shot up 20% in after-hours trading Monday after the biotech company and partner Ipsen (OTCPK:IPSEY) announced the presentation of positive results from a Phase 3 study of their drug elafibranor in the treatment



READ SOURCE

Readers Also Like:  Sensex gains 351 pts ahead of Fed rate decision; Nifty above 19,750; RIL, L&T, ITC rally

This website uses cookies. By continuing to use this site, you accept our use of cookies.